RecruitingNCT05667948

Molecular Analysis and Treatment Options of Thymic Malignancies

Molecular Landscape Analysis and Treatment Options for Thymic Epithelial Tumors


Sponsor

Shanghai Chest Hospital

Enrollment

500 participants

Start Date

Jan 1, 2016

Study Type

OBSERVATIONAL

Conditions

Summary

Thymic malignancies are the most common tumors of the anterior mediastinum, though surgery and radiation often effectively treat thymic carcinomas, a minority continue to progress and eventually lead to death. Therefore, there is an unmet need for more effective therapies for thymic malignancies. Considering the role of molecular alterations has yet to be defined in the treatment of thymoma and thymic malignancies, there is an urgent recognition that molecular alterations in the thymic malignancies are important to predict response and survival for novel targeted therapies. In summary, identification of genetic alterations in thymic malignancies is increasingly essential to perform molecular diagnostics and individualized treatments. This project aims to create a registry of patients with thymic malignancies to further the characterization of molecular alterations and develop (novel) treatments based on the detection.


Eligibility

Min Age: 18 Years

Inclusion Criteria3

  • Histologically proven diagnosis of thymic malignancies
  • years of age or older
  • Ability to understand and the willingness to sign a written informed consent document

Interventions

DRUGChemotherapy

different treatments based on the molecular analysis


Locations(1)

Xiaomin Niu

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05667948


Related Trials